CUMULOCITY
20.4.2016 18:25:05 CEST | Business Wire | Press release
Cumulocity, the global leading provider of ‘Internet-of-Things’ (IoT) software and solutions, and Astea International Inc., the leader in service management and mobile workforce solutions , have teamed up to offer the most advanced and comprehensive end-to-end service management solution available today.
As service delivery grows more complex and competitive, companies committed to achieving service excellence are looking to take advantage of IoT technologies to collect, analyze and act on real-time information from smart assets in the field. This will move the traditional service delivery model beyond the simple alert-dispatch-repair applications to a more proactive, predictive outcomes-based service model.
Cumulocity’s award winning IoT Platform enables companies to collect and analyze information in real-time from connected, smart assets and equipment. It also provides full remote control and management capability enabling for example remote configuration, software update or restart of any equipment. The integration between Cumulocity and Astea seamlessly links the assets in the field to the resources in the service organization so that they can more accurately predict equipment failures, create usage-based maintenance schedules, reduce the number of truck rolls, improve inventory utilization, and meet greater service level agreement (SLA) commitments with fewer resources.
Rapid Results
Specific benefits for customers include:
- Significantly lower service costs . Field and call center technicians are armed with the information they need to rapidly identify and resolve problems on the first contact.
- Greater customer satisfaction & retention. Proactive problem detection often resolves issues before they affect the customer, dramatically increasing product uptime.
- Increased service revenue. Rapid resolution and superior on-demand customer service drive opportunities for increased revenue through new service offerings and business models.
“Cumulocity provides a complete solution for connecting smart assets and analyzing the information in real-time to turn it into intelligent actions. This ability to turn data into action is what creates real business value and we are excited to be working with Astea as their strategic partner for IoT. With this integration, enterprise service organizations will be able to take advantage of real-time information provided by their assets in the field in ways that will improve service, reduce costs, and create new service revenue opportunities and differentiated offerings,” says Jari Salminen, Managing Director at Cumulocity.
“Our customers are demanding greater responsiveness, improved first-time fix rates, and guaranteed equipment uptime. The next generation of service delivery will be more proactive/predictive instead of primarily reactive,” said Deb Geiger, VP Global Marketing, Astea International. “To fulfil this vision, we have selected Cumulocity as our strategic IoT platform and are excited about the opportunities this collaboration brings to our customers,” she continues.
Cumulocity and Astea will be holding a free webinar demonstrating the powerful benefits that this joint solution can offer for service organizations interested in unlocking the potential of IoT. Be among the first to get an exclusive demonstration on Wednesday, May 4, 2016, at 10:30am ET/4:30pm CEST to reserve your spot please visit: Simplifying The Internet of Things for Field Service .
About Cumulocity
Cumulocity is the leading independent Application Enablement and Device Management platform for the Internet-of-Things (IoT) – since 2010. Cumulocity is an open platform that provides a complete feature set for rapidly developing and deploying IoT solutions. The key features include Data collection and Storage, Real-Time Analytics, Real-Time Visualization and Device Management. Our open and publicly documented APIs and the open UI framework, enable our partners and customers to configure and extend the platform to their unique needs.
Scalability, security and reliability are critical in IoT solutions - and our origins as part of Nokia Siemens Networks, the world's mobile broadband specialist, gives us the experience of securely managing millions of devices without service interruptions. And being available both as Cloud and On-Premise deployments, Cumulocity enables enterprises to start small and scale out to millions of devices with the deployment model fit for their business.
For more information and to start your free trial visit www.cumulocity.com .
About Astea International
Astea International is a global provider of software solutions that offer all the cornerstones of service lifecycle management, including customer management, service management, asset management, forward and reverse logistics management and mobile workforce management and optimization. Astea’s solutions link processes, people, parts, and data to empower companies and provide the agility they need to achieve sustainable value in less time, and successfully compete in a global economy. Since 1979, Astea has been helping more than 600 companies drive even higher levels of customer satisfaction with faster response times and proactive communication, creating a seamless, consistent and highly personalized experience at every customer relationship touch point.
www.astea.com. Service Smart. Enterprise Proven.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420006186/en/
Contact:
Cumulocity
Contact: Philip Hooker
E-mail: mediarelations@cumulocity.com
http://www.cumulocity.com
Phone:
+49 (211) 74951433
or
Astea International
Debbie Geiger
Vice
President, Marketing
215-682-2500
dgeiger@astea.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
